A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2027

Conditions

Extramammary Paget DiseaseScrotum Disease

Interventions

DRUG

Disitamab Vedotin combined with Bicalutamide

Single Group Assignment

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

collaborator

Fujian Province Tumor Hospital

OTHER

collaborator

Qinghai Province Cancer Hospital

UNKNOWN

lead

Fudan University

OTHER

NCT07117851 - A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease | Biotech Hunter | Biotech Hunter